BioPlus (NASDAQ:BIOS) announced this morning that it has mutually terminated its combination with medical device company Avertix.
Unlike with many terminations seen recently, this parting of ways does not appear to have come directly as a result of discouraging redemption results ahead of a major vote and the two sides are still well away from their December 31 outside date.
But, Avertix said in the press release that the two sides “agreed that the current market conditions are not conducive to completing the transaction on terms acceptable to both BIOS and Avertix stakeholders”.
At issue could have been the difficult terms for securing additional outside capital. BioPlus planned to pull together a $50 million PIPE at announcement and was beholden to a $40 million minimum cash condition. The two sides had not made any financing announcements since and in the current risk-off environment, many of the options available require concessions from either sponsor or target.
BioPlus CEO Ross Haghighat has insight into both sides interest as he also already has been serving as Avertix’s executive chairman and will continue on there despite the termination. It is the end of the road for BioPlus, however.
The SPAC noted that it will not seek an alternative business combination and will liquidate as soon as practicable beginning October 4 with a redemption rate of $10.79 after dissolution expenses.
Though unfortunate, the moves come alongside a bright spot of news among biotech de-SPACs as POINT Biopharma (NASDAQ:PNT) just announced it has agreed to be acquired at $12.50 per share by peer Eli Lilly (NYSE:LLY).
Shepherd Ave Capital Acquisition Corp. (Nasdaq: SPHAU) is the latest SPAC to file to IPO, making 24 new registration statements that have filed since June 1, 2024. So far, only two of those 24 have gone public, but it does indicate an active August. In SPACLand at least, August is never slow. As for Shepherd...
At the SPAC of Dawn SPACs have now priced 20 IPOs seven months into 2024 with an eye on beating 2023’s total of 31 IPOs. With a little more than 5 months left in the year, it’s expected that SPACs should at least match that number by only needing to price roughly two IPOs per...
DT Cloud Star announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “DTSQU”, Thursday, July 25, 2024. The new SPAC aims to combine with an established business with long-term financial visibility, but has not limited itself to a particular industry or sector....
Launch Two (NASDAQ:LPBBU) has filed for a $200 million IPO that shows how the market has shifted for new issuance since its sister SPAC Launch One (NASDAQ:LPAAU) filed just over a month ago. Both SPACs are underwritten by Cantor Fitzgerald and seeking nominally the same raise at IPO, but Launch Two is overfunding its trust...
FTAC Emerald (NASDAQ:EMLD) has entered into a definitive agreement to combine with crypto fintech firm Fold at an enterprise value of $381 million. Phoenix, Arizona-based Fold provides digital banking services backed by a treasury of Bitcoin that includes FDIC-secured checking accounts as well Bitcoin trading and awards. The combined company is expected to trade on...